Literature DB >> 26552973

In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms.

Maiken Cavling Arendrup1, Rasmus Hare Jensen2, Manuel Cuenca-Estrella3.   

Abstract

ASP2397 is a new compound with a novel and as-yet-unknown target different from that of licensed antifungal agents. It has activity against Aspergillus and Candida glabrata. We compared its in vitro activity against wild-type and azole-resistant A. fumigatus and A. terreus isolates with that of amphotericin B, itraconazole, posaconazole, and voriconazole. Thirty-four isolates, including 4 wild-type A. fumigatus isolates, 24 A. fumigatus isolates with alterations in CYP51A TR/L98H (5 isolates), M220 (9 isolates), G54 (9 isolates), and HapE (1 isolate), and A. terreus isolates (2 wild-type isolates and 1 isolate with an M217I CYP51A alteration), were analyzed. EUCAST E.Def 9.2 and CLSI M38-A2 MIC susceptibility testing was performed. ASP2397 MIC50 values (in milligrams per liter, with MIC ranges in parentheses) determined by EUCAST and CLSI were 0.5 (0.25 to 1) and 0.25 (0.06 to 0.25) against A. fumigatus CYP51A wild-type isolates and were similarly 0.5 (0.125 to >4) and 0.125 (0.06 to >4) against azole-resistant A. fumigatus isolates, respectively. These values were comparable to those for amphotericin B, which were 0.25 (0.125 to 0.5) and 0.25 (0.125 to 0.25) against wild-type isolates and 0.25 (0.125 to 1) and 0.25 (0.125 to 1) against isolates with azole resistance mechanisms, respectively. In contrast, MICs for the azole compounds were elevated and highest for itraconazole: >4 (1 to >4) and 4 (0.5 to >4) against isolates with azole resistance mechanisms compared to 0.125 (0.125 to 0.25) and 0.125 (0.06 to 0.25) against wild-type isolates, respectively. ASP2397 was active against A. terreus CYP51A wild-type isolates (MIC 0.5 to 1), whereas MICs of both azole and ASP2397 were elevated for the mutant isolate. ASP2397 displayed in vitro activity against A. fumigatus and A. terreus isolates which was independent of the presence or absence of azole target gene resistance mutations in A. fumigatus. The findings are promising at a time when azole-resistant A. fumigatus is emerging globally.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26552973      PMCID: PMC4704222          DOI: 10.1128/AAC.02336-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Factors associated with mortality in transplant patients with invasive aspergillosis.

Authors:  John W Baddley; David R Andes; Kieren A Marr; Dimitrios P Kontoyiannis; Barbara D Alexander; Carol A Kauffman; Robert A Oster; Elias J Anaissie; Thomas J Walsh; Mindy G Schuster; John R Wingard; Thomas F Patterson; James I Ito; O Dale Williams; Tom Chiller; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

3.  Factors associated with overall and attributable mortality in invasive aspergillosis.

Authors:  Yasmine Nivoix; Michel Velten; Valérie Letscher-Bru; Alireza Moghaddam; Shanti Natarajan-Amé; Cécile Fohrer; Bruno Lioure; Karin Bilger; Philippe Lutun; Luc Marcellin; Anne Launoy; Guy Freys; Jean-Pierre Bergerat; Raoul Herbrecht
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

4.  Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany.

Authors:  J Steinmann; A Hamprecht; M J G T Vehreschild; O A Cornely; D Buchheidt; B Spiess; M Koldehoff; J Buer; J F Meis; P-M Rath
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

5.  Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality.

Authors:  Arlo Upton; Katharine A Kirby; Paul Carpenter; Michael Boeckh; Kieren A Marr
Journal:  Clin Infect Dis       Date:  2007-01-09       Impact factor: 9.079

6.  Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007).

Authors:  O Lortholary; J-P Gangneux; K Sitbon; B Lebeau; F de Monbrison; Y Le Strat; B Coignard; F Dromer; S Bretagne
Journal:  Clin Microbiol Infect       Date:  2011-06-10       Impact factor: 8.067

7.  Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene.

Authors:  Shawn R Lockhart; João P Frade; Kizee A Etienne; Michael A Pfaller; Daniel J Diekema; S Arunmozhi Balajee
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

8.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

9.  Caspofungin for the treatment of candidaemia in patients with haematological malignancies.

Authors:  L Pagano; L Fianchi; R Fanci; A Candoni; M Caira; B Posteraro; M Morselli; C G Valentini; G Farina; M E Mitra; M Offidani; M Sanguinetti; M E Tosti; A Nosari; G Leone; P Viale
Journal:  Clin Microbiol Infect       Date:  2009-06-22       Impact factor: 8.067

10.  Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009.

Authors:  Jan W M van der Linden; Eveline Snelders; Greetje A Kampinga; Bart J A Rijnders; Eva Mattsson; Yvette J Debets-Ossenkopp; Ed J Kuijper; Frank H Van Tiel; Willem J G Melchers; Paul E Verweij
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

View more
  11 in total

1.  A Cationic Polymer That Shows High Antifungal Activity against Diverse Human Pathogens.

Authors:  Leslie A Rank; Naomi M Walsh; Runhui Liu; Fang Yun Lim; Jin Woo Bok; Mingwei Huang; Nancy P Keller; Samuel H Gellman; Christina M Hull
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against Aspergillus Species through a Specific Transporter.

Authors:  Ikuko Nakamura; Keisuke Ohsumi; Shinobu Takeda; Kiyomitsu Katsumata; Satoru Matsumoto; Souichiro Akamatsu; Hikaru Mitori; Toru Nakai
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397.

Authors:  Anna-Maria Dietl; Matthias Misslinger; Mario M Aguiar; Vasyl Ivashov; David Teis; Joachim Pfister; Clemens Decristoforo; Martin Hermann; Sean M Sullivan; Larry R Smith; Hubertus Haas
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 4.  Novel Antifungal Agents and Their Activity against Aspergillus Species.

Authors:  Roya Vahedi-Shahandashti; Cornelia Lass-Flörl
Journal:  J Fungi (Basel)       Date:  2020-10-09

5.  A Novel Polyaminocarboxylate Compound To Treat Murine Pulmonary Aspergillosis by Interfering with Zinc Metabolism.

Authors:  Paris Laskaris; Rocío Vicentefranqueira; Olivier Helynck; Grégory Jouvion; José Antonio Calera; Laurence du Merle; Franck Suzenet; Frédéric Buron; Rodolphe Alves de Sousa; Daniel Mansuy; Jean-Marc Cavaillon; Jean-Paul Latgé; Hélène Munier-Lehmann; Oumaima Ibrahim-Granet
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 6.  Advantages of the Silkworm As an Animal Model for Developing Novel Antimicrobial Agents.

Authors:  Suresh Panthee; Atmika Paudel; Hiroshi Hamamoto; Kazuhisa Sekimizu
Journal:  Front Microbiol       Date:  2017-03-07       Impact factor: 5.640

Review 7.  Treatment of Aspergillosis.

Authors:  Jeffrey D Jenks; Martin Hoenigl
Journal:  J Fungi (Basel)       Date:  2018-08-19

Review 8.  Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.

Authors:  Nathan P Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-08-16

Review 9.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07

Review 10.  Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus.

Authors:  Nilce M Martinez-Rossi; Tamires A Bitencourt; Nalu T A Peres; Elza A S Lang; Eriston V Gomes; Natalia R Quaresemin; Maíra P Martins; Lucia Lopes; Antonio Rossi
Journal:  Front Microbiol       Date:  2018-05-29       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.